Bristol Myers Squibb (BMS) announced late-breaking data Wednesday showing that deucravacitinib, an allosteric tyrosine kinase 2 inhibitor, met the primary endpoint in the treatment of systemic lupus erythematosus.
Tag Archive for: Bristol-Myers Squibb
The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.
Genentech, a member of the Roche group, announced new data on Thursday related to the company’s investigational CD20xCD3 T-cell engaging bispecific antibody glofitamab, which is intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Nearly one third of patients with ulcerative colitis who received an experimental Pfizer Inc. medicine in a clinical trial were in remission after a year of treatment, the drugmaker said on Tuesday.